Cargando…

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy. Their structure combines highly potent anti-cancer drugs (payloads or warheads) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barreca, Marilia, Lang, Noémie, Tarantelli, Chiara, Spriano, Filippo, Barraja, Paola, Bertoni, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834635/ https://www.ncbi.nlm.nih.gov/pubmed/36654819 http://dx.doi.org/10.37349/etat.2022.00112

Ejemplares similares

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022)

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
por: Gaudio, Eugenio, et al.
Publicado: (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
por: Hicks, Stuart W., et al.
Publicado: (2019)

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
por: Guidetti, Francesca, et al.
Publicado: (2023)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

HSV-1 Glycoprotein D and Its Surface Receptors: Evaluation of Protein–Protein Interaction and Targeting by Triazole-Based Compounds through In Silico Approaches
por: Bivacqua, Roberta, et al.
Publicado: (2023)

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
por: Barreca, Marilia, et al.
Publicado: (2020)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021)

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
por: Tarantelli, Chiara, et al.
Publicado: (2019)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Novel insights on [1,2]oxazolo[5,4‐e]isoindoles on multidrug resistant acute myeloid leukemia cell line
por: Labbozzetta, Manuela, et al.
Publicado: (2022)

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
por: Tarantelli, Chiara, et al.
Publicado: (2021)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018)

Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
por: Jackson, Dowdy, et al.
Publicado: (2014)

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
por: Spanò, Virginia, et al.
Publicado: (2021)

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
por: Chu, Yurou, et al.
Publicado: (2021)

An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
por: Pal, Lal Bahadur, et al.
Publicado: (2023)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
por: Spanò, Virginia, et al.
Publicado: (2020)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
por: Bosco, Emily E., et al.
Publicado: (2018)

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
por: Groothuis, Patrick G., et al.
Publicado: (2023)

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
por: Gogia, Pooja, et al.
Publicado: (2023)

Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
por: Krytska, Kateryna, et al.
Publicado: (2022)

Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia
por: Le, Quy, et al.
Publicado: (2023)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
por: Brignole, Chiara, et al.
Publicado: (2023)

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy
por: Zhang, Shuyong, et al.
Publicado: (2021)

A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022)

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma
por: Zhu, Bing, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives
por: Sganga, Stefano, et al.
Publicado: (2023)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u24bc33he8tvto5smktmimbcah